Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 63, Issue 7, 2004, Pages 797-803

  Capell, H A ^a   Madhok, R ^a   Hunter, J A ^b   Porter, D ^b   Morrison, E ^c   Larkin, J ^d   Thomson, E A ^b   Hampson, R ^a   Poon, F W ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; BONE EROSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG SCREENING; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; MALE; MOUTH ULCER; NAUSEA AND VOMITING; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISOLONE; STATISTICS, NONPARAMETRIC; SULFASALAZINE;

EID: 3042739344     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.014050     Document Type: Article

References (32)

1. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. Edinburgh: SIGN Executive, Royal College of Physicians of Edinburgh, No 48, December 2000.
2. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone: Compound E) and of pituitary adrenocorticotropnic hormone on rheumatoid arthritis. Preliminary report. Prof Staff Meet Mayo Clin 1949;24:181-97.
3. Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959;18:173-87.
4. Corkhill M, Kirkham BW, Chikanza IC, Gibson T, Panayi GS. Intramuscular depot methylprednisolone induction of chrysotnerapy in rheumatoid arthritis: a randomised clinical trial. Br J Rheumatol 1990;29:274-9.
5. van Gestel AM, Loan RFJM, Haagsma G, van de Putte LBA, van Riel PLVM. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol 1995;34:347-51.
6. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side-effects. Ann Rheum Dis 1999;58:713-18.
7. Kirwan JR for the Arthritis and Rheumatism Council low-dose glucocorticoid study group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
8. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early RA. Arthritis and Rheumatism Council low dose glucocorticoid study group. Br J Rheumatol 1998;37:930-6.
9. Van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR, Bijlsma JWJ. Low-dose prednisolone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side-effects: o randomised, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
10. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
11. Boers M. The case for corticosteroids in the treatment of early rheumatoid arthritis. Rheumatology 1999;38:95-7.
12. Morrison E, Capell HA. Corticosteroids in rheumatoid arthritis - the case against. Rheumatology 1999;38:97-100.
13. de Nijs RNJ, Jacobs JWG, Bijlsma JWJ, Lems WF, Loan RFJM, Houben HHM, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 2001;40:1375-83.
14. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-6.
15. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 1997;103:31-9S.
16. Saag KG. Resolved: low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Care Res 2001;45:468-71.
17. Wolfe F, Mifchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
18. Arnett FC, Edworthy SM, Bloch DA, McShare DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987: Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443-53.
20. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does [Editorial]. BMJ 1998;317:362-3.
21. Department of Health. Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Statement on vitamin B6 (pyridoxine) toxicity. London: Department of Health, 1997.
22. Carstairs V, Morris R. Deprivation and health in Scotland. Aberdeen: Aberdeen University Press, 1991.
23. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;147:393-406.
24. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
25. Kirwan JR, Reeback JS. Standford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
26. van der Heijde DMFM. Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-53.
27. Bruynesteyn K, van der Heijde D, Boers M, Soudan A, Peloso P, Paulus H, et al. Reading films with or without known sequence: does it influence the accuracy to detect clinically important changes in the individual [abstract]. San Francisco: ACR 65th Annual Scientific Meeting, November, 2001.
28. Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BAC. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
29. Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor if increasing severity of radiographic erosions in rheumatoid arthritis. Arthritis Rheum 2002;46:906-12.
30. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
31. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
32. Crilly A, Maiden N, Capell HA, Madhok R. Genotyping for disease associated HLA DR β1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation. Ann Rheum Dis 1999;58:114-17.